65,437 trials
COPD
Primary: Time to All-cause Mortality or Re-hospitalization During the 180 Days Post-randomization. — 54; 55 Days to event — p=<0.1
Depression · Breast Cancer Screening · Cervical Cancer Screening
Primary: Assessment of Colorectal, Breast, and Cervical Cancer Screening Up to Date Status — 22.0; 26.9; 56.9; 52.8 Percentage (%) of Participants — p=0.2562
Peripheral Artery Disease · PAD · Peripheral Arterial Disease
Primary: Levels of Unacylated Ghrelin — 71.34; 58.01; 59.96; 845.57 pg/ml
Mild Gestational Diabetes
Primary: Mean Fetal Weight at Birth — 3355; 3322 grams
Diabetes · Diabetes Mellitus, Type 2
Primary: Number of Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Maintenance 2 (36 Weeks) — 216.8; 243.9 Episodes/(PYE*100) — p=0.1715
Neuroblastoma
Primary: Incidence of Infection — 6 infections
Herpes Zoster
Primary: Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) — 5175; 963; 4422 Participants
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin (HbA1c) — -0.15; -0.09 Percentage of HbA1c — p=0.310
Myelomonocytic Leukemia
Primary: The Maximum Tolerated Dose (MTD) of Ruxolitinib for the Treatment of Myelomonocytic Leukemia (CMML) — 40 mg
Sexual Dysfunction · Sexual Arousal Disorder · Sexual Dysfunction, Physiological
Primary: Change in Delayed Orgasm Grade — -0.33 Grade
Mastectomy
Primary: Pain Intensity (on the 0-10 Pain Intensity Numeric Scale) — 1.9; 2.1 score on a scale
Lung Diseases · Ultrasonography · Fiberoptic Bronchoscopy
Primary: Number of Patients of Lung Collapse in Ultrasonography and Fiberoptic Bronchoscopy — 89; 83 Participants
Tobacco Use Disorder
Primary: Assessment of Bioequivalence of Prototype Mini Lozenges With Nicorette Mini Lozenge by Measuring Area Under the Plasma Concentration Versus Time Curve From Time Zero to…
Dysphonia
Primary: Change in Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V) Score From Baseline to 2 Months — 0.72; 0.65 score on a scale
Head and Neck Cancer · Precancerous Condition
Primary: Number of Participants With Objective Response Based on Histologic Grade — 13; 6 Participants